# Pharmacokinetics Study of ALO-02 and OxyContin

> **NCT01557257** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 13 (actual)

## Conditions studied

- Management of Moderate to Severe Pain

## Interventions

- **DRUG:** ALO-02
- **DRUG:** Naltrexone block
- **DRUG:** ALO-02
- **DRUG:** Naltrexone block
- **DRUG:** OxyContin
- **DRUG:** Naltrexone block

## Key facts

- **NCT ID:** NCT01557257
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03
- **Primary completion:** 2012-05
- **Final completion:** 2012-05
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2012-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01557257

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01557257, "Pharmacokinetics Study of ALO-02 and OxyContin". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01557257. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*